Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025
December 17, 2024 15:00 ET
|
Nordicus Partners Corporation
BEVERLY HILLS, California, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB:NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic...
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
December 11, 2024 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage biopharmaceutical company that had been developing a...
NORDICUS now trading under symbol NORD
December 10, 2024 07:00 ET
|
Nordicus Partners Corporation
BEVERLY HILLS, California, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB:NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic...
Biopharmaceutical Excipients Market to Reach USD 4.04 Billion by 2032, Driven by Growing Demand for Advanced Biologics | Research by SNS Insider
December 04, 2024 08:01 ET
|
SNS Insider pvt ltd
Austin, United States, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical Excipients Market Size & Growth Analysis: According to SNS Insider Research, The Biopharmaceutical Excipients Market...
Halberd Update on WatchDawg® PTSD Treatment
December 02, 2024 08:00 ET
|
Halberd Corp.
Halberd Update on WatchDawg® PTSD Treatment
IBN Initiates Coverage of Kairos Pharma Ltd.
November 26, 2024 08:30 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Nov. 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics,...
Greenwich LifeSciences Partners with GIM in Italy
November 26, 2024 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
November 21, 2024 05:30 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
Nordicus Partners Corporation Acquires the Remaining 5% Shares In Orocidin A/S
November 12, 2024 09:15 ET
|
Nordicus Partners Corporation
Beverly Hills, California., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing...
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
November 12, 2024 05:30 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform